--- title: "Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial" id: "bmj-open-19-adjuvant-short-course-radiotherapy-combined-with-chemotherapy-and-a-pd-1-inhibitor-for-resected-mucosal-melanoma-study-protocol-for-a-single-arm-prospective-phase-ii-trial" canonical_url: "https://medichelpline.com/clinical-feed/bmj-open-19-adjuvant-short-course-radiotherapy-combined-with-chemotherapy-and-a-pd-1-inhibitor-for-resected-mucosal-melanoma-study-protocol-for-a-single-arm-prospective-phase-ii-trial" content_type: "clinical_feed_article" specialty: "Research Highlights" source_name: "BMJ Open" source_url: "http://bmjopen.bmj.com/cgi/content/short/16/4/e114414?rss=1" published_at: "2026-04-16T14:54:51.000Z" evidence_level: "Journal Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # Adjuvant short-course radiotherapy combined with chemotherapy and a PD-1 inhibitor for resected mucosal melanoma: study protocol for a single-arm, prospective, phase II trial ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-open-19-adjuvant-short-course-radiotherapy-combined-with-chemotherapy-and-a-pd-1-inhibitor-for-resected-mucosal-melanoma-study-protocol-for-a-single-arm-prospective-phase-ii-trial - **Specialty:** [Research Highlights](https://medichelpline.com/clinical-feed/research-highlights.md) - **Primary Source:** BMJ Open - **Source URL:** [Original Journal Publication](http://bmjopen.bmj.com/cgi/content/short/16/4/e114414?rss=1) - **Published At:** 2026-04-16T14:54:51.000Z - **Evidence Rating:** Journal Feed ## Executive GIST (TL;DR) Introduction Mucosal melanoma (MM) carries a high risk of postoperative relapse and poorer survival than cutaneous disease. Prospective data from China support adjuvant temozolomide - cisplatin (TMZ/DDP) in resected MM, while radiotherapy (RT) may augment antitumour immunity and synergise with programmed death 1 (PD-1) inhibitor. We therefore designed an adjuvant regimen combining short-course RT (SCRT) with chemotherapy and PD-1 inhibitor after curative-intent resection. Methods and analysis This investigator-initiated, single-arm, prospective, phase II study at Fudan University Shanghai Cancer Centre enrols adults (≥18 years) with histologically confirmed MM after R0/R1 resection, Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1 and M0 disease. Patients receive six 3-week cycles of systemic therapy: pucotenlimab 200 mg IV on day 1; TMZ 200 mg/m² orally on days 1 - 5 and DDP 25 mg/m² IV on days 1 - 3. (SCRT; 25 Gy in five fractions) is delivered after the first two cycles of systemic therapy, followed by four additional cycles of systemic therapy without RT. The primary endpoint is 1-year recurrence-free survival (RFS). Secondary endpoints include locoregional RFS, distant metastasis-free survival, overall survival and safety (CTCAE V.5.0). The planned sample size is 47 (44 evaluable), providing 80% power (one-sided α of 0.10) to detect an improvement in 1-year RFS from 55% to 70%. Time-to-event endpoints will be estimated using Kaplan - Meier methods with 95% CIs. Ethics and dissemination The protocol was approved by the Ethics Committee of Fudan University Shanghai Cancer Centre (approval number: 2407300-5), and all participants will provide written informed consent. Findings will be disseminated in peer-reviewed journals and at scientific conferences. Trial registration number ChiCTR2400093001. ## Clinical Analysis & Structured Key Points Introduction Mucosal melanoma (MM) carries a high risk of postoperative relapse and poorer survival than cutaneous disease. Prospective data from China support adjuvant temozolomide - cisplatin (TMZ/DDP) in resected MM, while radiotherapy (RT) may augment antitumour immunity and synergise with programmed death 1 (PD-1) inhibitor. We therefore designed an adjuvant regimen combining short-course RT (SCRT) with chemotherapy and PD-1 inhibitor after curative-intent resection. Methods and analysis This investigator-initiated, single-arm, prospective, phase II study at Fudan University Shanghai Cancer Centre enrols adults (≥18 years) with histologically confirmed MM after R0/R1 resection, Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1 and M0 disease. Patients receive six 3-week cycles of systemic therapy: pucotenlimab 200 mg IV on day 1; TMZ 200 mg/m² orally on days 1 - 5 and DDP 25 mg/m² IV on days 1 - 3. (SCRT; 25 Gy in five fractions) is delivered after the first two cycles of systemic therapy, followed by four additional cycles of systemic therapy without RT. The primary endpoint is 1-year recurrence-free survival (RFS). Secondary endpoints include locoregional RFS, distant metastasis-free survival, overall survival and safety (CTCAE V.5.0). The planned sample size is 47 (44 evaluable), providing 80% power (one-sided α of 0.10) to detect an improvement in 1-year RFS from 55% to 70%. Time-to-event endpoints will be estimated using Kaplan - Meier methods with 95% CIs. Ethics and dissemination The protocol was approved by the Ethics Committee of Fudan University Shanghai Cancer Centre (approval number: 2407300-5), and all participants will provide written informed consent. Findings will be disseminated in peer-reviewed journals and at scientific conferences. Trial registration number ChiCTR2400093001. ## Related Clinical Research - [Avoiding Cardiac Toxicity with Immune Checkpoint Inhibitors: Safety Review (Title Only Available)](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-avoidance-of-cardiac-toxicity-during-the-application-of-immune-checkpoint.md) - [GLUT10 (SLC2A10) Expression in Breast Cancer and Its Role in Cisplatin Resistance](https://medichelpline.com/clinical-feed/pubmed-42595549.md) (DOI: 10.3760/cma.j.cn112152-20251018-00521) - [Gene-based immunotherapy in osteosarcoma: full article text not available on source page](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-gene-based-immunotherapy-in-osteosarcoma-from-oncolytic-vectors-to-engineered.md) - [PD-L1 expression and survival in unresectable or recurrent gastric cancer treated with first-line](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-pd-l1-expression-and-survival-in-unresectable-recurrent-gastric-cancer-treated.md) - [Targeting ANGPTL4/NRP1/ABL1/RAD51 Axis Reverses Cisplatin Resistance in Head and Neck Cancer](https://medichelpline.com/clinical-feed/pnas-67-targeting-the-angptl4-nrp1-abl1-rad51-axis-reverses-cisplatin-resistance-by-impairing-dna-damage-repair-in-head-and-neck-cancer.md) ## Navigation - [← Back to Research Highlights Feed](https://medichelpline.com/clinical-feed/research-highlights.md) - [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.